Tumor-antigen focused immunotherapies anticipating tumor plasticity, resistance to treatments and relapses ✔️🟣

Brenus Pharma, french private start-up in biotechnology based in Lyon, develops a platform technology to deliver first-in-class tumor-antigen focused immunotherapy.

The STC (Stimulated Tumor Cells) Technology allogeneic platform deliver STC drug product, in 3 major steps:

🟣 Cell Selection to mimic tumor heterogeneity & resistance capacities of the selected indication.

🟣 In vitro induction and overexpression of resistances marker by stimulation with Standard of care and Rx.
• 100+ cancer related surface proteins over expressed
• Cross-matching human tumoral biopsy databases
• Covering 3 categories of targets (Tumor Specific - Resistances to treatment - Tumor Plasticity)

🟣Tag of this resistances markers by Haptenization process, to make it visible by patient’s immune system.

Its mimic patient's relapsing conditions in vitro and educates patient's immune system to recognize cancer-related antigens driven by relapse mechanism when it will be injected in combination with current treatment.

👉 Like a therapeutic vaccine, STC product anticipates risks of tumor escape and the STC Platform answers huge unmet need in solid tumor by addressing limits of current treatment.
—————————————————
📢 Brenus has initiated a solid internal knowledge thanks to this collaboration between J.Gardette, co-Founder and renowned healthcare entrepreneur, DG at BIOCORP (health-tech company specialized in the design, development, and manufacturing of innovative medical devices) and B.Pinteur PharmD, co-Founder & CSO, specialized in innovative cellular therapies and founder of BioElpida (Biotechnology company specialized in innovative therapies’ manufacturing). Joined by P. Bravetti PharmD, HEC, CEO, Medical & Marketing expert with previous international experiences at Roche, Servier and Takeda Oncology; their knowledge has already proven its efficacy by overcoming many challenges within a competitive landscape & immuno-oncology technological constraints.